Additionally, the government did not intervene in the action. BPI also told Hunterbrook Media that it is a FDA registered complex generic and NDA drug manufacturer and as such all our operations are conducted under the strict standards required by those regulations, including the Current Good Manufacturing PracticeGuidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Compounding pharmacies have for decades provided additional supply in shortage and customized dosages that are not available from other manufacturers
Regional Insights North America commands the largest market share in the global Glucagon-like Peptide 1 (GLP-1) Analogues market, supported by high obesity and diabetes prevalence, rapid FDA approvals for weight-loss indications (Wegovy, Zepbound), strong reimbursement for GLP-1 therapies, advanced healthcare infrastructure, and significant R&D investment by leading pharmaceutical companies
10.1146/annurev.neuro.31.060407.125631 Annu
P.WedemeyerH.SingerA.KhomutjanskajaN.DienesH
2020 janv.:151:104554
Journal of Cell Biology , 166 (2), 157159
